Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study

Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis, which are often difficult to treat. The aim of this phase 3, open‐label study was to evaluate efficacy and safety of guselkumab, a human interleukin‐23 monoclonal antibody, in Japanes...

Descripción completa

Detalles Bibliográficos
Autores principales: Sano, Shigetoshi, Kubo, Hiroshi, Morishima, Hitomi, Goto, Ryosuke, Zheng, Richuan, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947137/
https://www.ncbi.nlm.nih.gov/pubmed/29569397
http://dx.doi.org/10.1111/1346-8138.14294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947137/
https://www.ncbi.nlm.nih.gov/pubmed/29569397
http://dx.doi.org/10.1111/1346-8138.14294

Ejemplares similares